June 11, 2020 / 9:42 PM / a month ago

BRIEF-Cytodyn Reached Its Enrollment Target For Phase 2 COVID-19 Trial For Mild To Moderate Indication

June 11 (Reuters) - Cytodyn Inc:

* CYTODYN REACHED ITS ENROLLMENT TARGET FOR PHASE 2 COVID-19 TRIAL FOR MILD TO MODERATE INDICATION – PRIMARY END POINT ANNOUNCEMENT IS NEXT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below